Pre-Rulemaking – Stakeholder Feedback
These following documents are in draft form and have not been approved by the department to begin the formal rulemaking process to establish a new rule or amend an existing rule. The purpose of providing these drafts to the public, and seeking feedback, is to obtain feedback and work with stakeholders in a collaborative way to increase our understanding of potential impacts, provide clarity regarding the intended objective and work to resolve issues prior to the formal rulemaking process.
| Regulation | Summary | Draft Language |
Fiscal Note(s) | Deadline for Comments | Comments |
|---|---|---|---|---|---|
| This proposed rule exempts certain anabolic steroid products from the licensing, distribution, recordkeeping, and reporting provisions of 19 CSR 30 (Controlled Substances) if the products have received approval as an exempt anabolic steroid product pursuant to 21 C.F.R. 1308.34. This proposed amendment modifies and updates 19 CSR 30-1.006 to reflect the current exemption list of anabolic steroid products provided by federal regulation. Persons who handle anabolic steroid products on the exemption list are exempt from the registration, records, reports, prescriptions, physical security and import and export requirements associated with Schedule III substances. | N/A | June 20, 2025 | Submit |